R
heumatoid arthritis (RA) is a chronic autoimmune disease of unknown cause characterised by synovial inflammation and subsequent damage of cartilage and underlying bone. RA synovial tissue is infiltrated by activated macrophages, dendritic cells, and T cells and shows evident synovial hyperplasia and neoangiogenesis. Despite extensive research on the immunological mechanisms involved, the exact pathophysiological pathways remain unclear. It is currently well accepted that a complex system, in which numerous inflammatory cells, chemokines, and cytokines are implicated, dominates the inflammatory cascade of RA. Involvement of the cytokines tumour necrosis factor a (TNFa), interleukin (IL)1, and IL6 has been studied thoroughly. The proinflammatory cytokines TNFa and IL1 are crucial in RA and their neutralisation results in clinical and radiological improvement. 1 2 Other cytokines regulate the balance between Th1 (IL12) and Th2 (IL10) immune reactions. [3] [4] [5] Both clinical and experimental evidence strongly suggests a cytokine balance skewed towards Th1 responses in arthritis. [6] [7] [8] Dendritic cells (DC) are professional antigen presenting cells which orchestrate innate and adaptive immune responses 9 and have a critical role in the regulation of both peripheral and central tolerance. 10 11 In addition, DC are producers of large amounts of pro-and anti-inflammatory cytokines and chemokines which attract numerous effector cells to the site of inflammation. Nowadays, a large body of evidence points towards an important role for DC in both experimental arthritis 12 and RA. [13] [14] [15] [16] [17] Immature DC (iDC) are scattered throughout the body and are highly specialised for antigen uptake, which is mediated by several scavenger receptors including Fc gamma receptors (FccR). 18 19 After antigen uptake or stimulation by proinflammatory cytokines, DC are triggered to undergo full maturation. This process is characterised by down regulation of the receptors involved in antigen uptake. 20 We recently showed that DC obtained from patients with RA lack the normal down regulation of FccR during maturation. 15 Moreover, activated mature DC are abundantly present in synovial tissue from patients with RA and express high levels of FccRII in comparison with those of healthy subjects. 14 15 21 These data underline the potential role of DC during inflammatory processes in RA, both systemically and locally.
FccR in humans can be divided into activation (FccRI, FccRIIa, and FccRIII) and inhibitory (FccRIIb) subtypes. 22 23 FccRII and FccRIII are mainly involved in the binding of IgGantigen complexes (immune complexes (IC)), which are abundantly present in RA. 24 25 The relevance of IC and the coordinated expression of activation and inhibitory FccR in the activation of effector cells and experimental arthritis has been demonstrated in several studies. [26] [27] [28] Of high interest are the results obtained recently from a study which examined the potential role for FccR balance in the orchestration and polarisation of immune responses. 29 30 These studies clearly show that, depending on the balance between the opposing FccR subtypes, triggering by IC can lead to either maintenance of tolerance or initiation of immunity. Measurement of IL12 and IL10, two cytokines diametrically opposed in their action to instruct Th1/Th2 T cell profiles, suggested the importance of FccR activation in the balance of these cytokines. The importance of the inhibitory FccR subtype was further substantiated by the findings that only DC without an intact FccRIIb signalling pathway were able to show full maturation, activation, and T cell activation upon engagement of IC.
Taken together, these data are highly suggestive for a potential role for DC and FccR expression in the initiation and modulation of the inflammatory cascade during RA. Elucidation of the mechanisms responsible for the proinflammatory response and Th1 cytokine balance in RA is a prerequisite to the development of effective immunomodulatory treatments for RA as has been shown with genetically modified DC during experimental arthritis. 31 32 In this study we therefore investigated the production of proinflammatory cytokines (IL1, TNFa, and IL6), Th1 (interferon (IFN)c and IL12) cytokines, and Th2 (IL10) cytokines by immature and fully mature DC under basal conditions and after stimulation via FccR dependent and independent pathways in RA. This study provides firm evidence that triggering of DC via FccR dependent pathways leads to a diminished production of IL6 and TNFa, which is specific for RA. Furthermore, triggering of FccR down regulates production of IL12 whereas IL10 is clearly up regulated. These results may provide new clues for the therapeutic application of ex vivo ''trained'' DC to abrogate or diminish the Th1 driven inflammatory process in RA.
PATIENTS AND METHODS

Patients
A total of 26 patients with RA and 20 healthy controls were enrolled in the study. All patients fulfilled the American College of Rheumatology criteria 33 for RA and gave informed consent for the study. All patients were treated with disease modifying antirheumatic drugs alone or in combination with non-steroidal anti-inflammatory drugs. Excluded from the study were patients who received treatment with systemic steroids or biological agents. The medical ethics committee of the University Medical Centre, Nijmegen approved the study protocol.
Generation of monocyte derived DC Venous blood was collected in 10 ml lithium heparin Vacutainer tubes (Becton & Dickinson, Mountain View, CA) and the peripheral blood mononuclear cell fraction was obtained by density gradient centrifugation over FicollHypaque (Amersham Biosciences, Roosendaal, The Netherlands). After several stringent washing procedures the cells were allowed to adhere for 1 hour at 37˚C in RPMI-1640, Dutch modification (Life Technologies, Breda, The Netherlands), enriched with 2% heat inactivated human serum in six well culture plates (Costar, Badhoeverdorp, The Netherlands). Adherent monocytes were cultured in RPMI-1640, Dutch modification, supplemented with 10% heat inactivated fetal calf serum and antibiotic-antimycotic agent (Life Technologies) in the presence of 500 U/ml IL4 (Schering-Plough, Amstelveen, The Netherlands) and 800 U/ml granulocyte monocyte-colony stimulating factor (Schering-Plough) for 6 days. Fresh complete culture medium was added after 3 days.
At day 6 the iDC were harvested. To generate mDC, iDC were transferred to new six well culture plates and cultured for two more days in the presence of complete culture medium supplemented with 2 mg/ml lipopolysaccharide (LPS) (E coli, Sigma Chemicals, St Louis, MO). The expression of cell surface markers characterising both the iDC and mDC characteristics was checked by fluorescence activated cell sorter (FACS) techniques, as described previously. 15 Briefly, the first layer was attached after incubation of 1610 5 FccR dependent and independent stimulation of DC To investigate the effect of FccR dependent or independent stimulation on cytokine production by iDC, fresh medium with or without heat aggregated gamma immunoglobulins (HAGGS, final concentration 100 mg/ml) was added at day 6 and incubated for 48 hours. To study the effect of FccR triggering during DC maturation, iDC were stimulated with LPS on day 6 in the presence or absence of HAGGS for two more consecutive days. FccR independent triggering of iDC and mDC was achieved by adding interferon gamma (IFNc, final concentration 1000 U/ml, Boehringer Ingelheim, Ingelheim am Rhein, Germany) in the same manner as with HAGGS. HAGGS were obtained by heating human IgG (Sigma Chemicals) at 63˚C for 30 minutes. The solution was centrifuged at 12 000 g for 10 minutes thereafter, and the concentration of HAGGS was determined by reading the absorbance at 280 nm. Supernatants were collected at 48 hours depending on the assessment of iDC or DC during maturation, respectively. During the whole experiment, the same batch of heat inactivated fetal calf serum was used.
Radioimmunoassay (RIA) for IL1
Polyclonal antibodies for IL1b were kindly provided by Sclavo (Siena, Italy). Human recombinant IL1b was radiolabelled by the chloramine-T method. 35 The RIA was performed as previously described. 36 Briefly, all samples and standards were prepared and mixed with a standard buffer which contained 13 mM Na 2 EDTA, 0.02% sodium azide, 0.25% bovine serum albumin (Boehring, Marburg, Germany), and inactivating units aprotinine, pH 7.4 (Bayer, Leverkussen, Germany). For measurement of IL1b in supernatants, 10 ml of sample or standard was added to the buffer. The mixture was incubated for 1 day at room temperature. After the addition of tracer (about 7000 dpm/100 ml) the incubation was continued for two more days. Separation of bound and free tracer was achieved by the addition of 100 ml of a separation agent containing sheep antirabbit IgG and 0.01% rabbit IgG (Sigma, St Louis, MO). After incubation for 30 minutes, the antibody complex was completely precipitated by the addition of 1 ml 7.5% polyethylene glycol 6000 (Merck, Darmstadt, Germany). The range of the standard curve was 20-3000 pg/ml, with a sensitivity of 40 pg/ml. To minimise interassay variations, all samples from the same experiments were analysed in the same run in duplicate. The interassay variation of our RIA is estimated at (15%, whereas the intra-assay variation is (10%.
Enzyme linked immunosorbent assay (ELISA) for IL6, IL10, IL12, and TNFa IL6 was measured by using a commercially available ELISA (Pelikine Compact human IL6 ELISA kit, CLB, Amsterdam, The Netherlands) according to the manufacturer's instructions. 37 The lower limit of detection with this assay was 8 pg/ ml. IL10 (detection limit 3.9 pg/ml) concentration was assessed by an ELISA, as described recently. 38 In this system, a horseradish peroxidase system was used employing 3,39-5,59-tetramethylbenzidine as substrate (DAKO, Glostrup, Denmark). As primary and secondary antibody 9D7 and 12G8, obtained from Pharmingen, were used respectively, at a concentration of 1 mg/ml. The measurement of IL12p70 (detection limit 0.2 ng/ml) was performed by a specific sandwich ELISA. As primary and secondary antibodies antihuman IL12p70 and biotin labelled antihuman IL12p40/ 70 were used, respectively (Endogen, Woburn, MA). A streptavidin-horseradish peroxidase conjugate was used to specifically stain the biotin labelled monoclonal antibodies and was visualised by incubation with 3,39-5,59-tetramethylbenzidine substrate. Absorption was measured at 450 nm. TNFa production was measured by an ELISA (detection limit 2 pg/ml) using an experimental arrangement previously described for components of the plasminogen activator system. 39 
Statistical analysis
Differences between the DC from RA or healthy controls were calculated by the Mann-Whitney U test and Student's t test, as appropriate. Values of p were two sided and the level of significance was set at p,0.05.
RESULTS
Flow cytometric characterisation of immature and mature DC Figure 1 shows the results of the FACS analysis of a panel of membrane markers on iDC and mDC. As expected, iDC express high levels of FccR II and DC-SIGN, intermediate levels of FccRI and III, costimulatory (CD80 and CD86) and MHC molecules, and low levels of CD14 (the monocyte marker) and CD83 (mDC marker). Upon full maturation, DC clearly reflect an up regulation of costimulatory molecules CD83 and MHC, while the expression of FccRI, II, and IIIa and CD14 clearly decreased. As demonstrated before, 15 for the majority of markers, no differences were seen between the two groups for either the number of expressing cells (%) or the mean fluorescence intensity. Interestingly, a clear difference in expression of FccR was seen (fig 1) . Comparison of the two groups showed a significantly increased FccRII (CD32) expression (mean fluorescence intensity) on immature DC from patients with RA (n = 26) when compared with that of controls (n = 20) (186 (22) v 63 (21) (mean (SD), p = 0.002). Double staining procedures for CD83 and CD32 were performed to assess the percentage of mDC after LPS stimulation and to study the level of CD32 expression on CD83 positive cells. Fully matured DC from patients with RA expressed significantly higher levels of CD32 than those of healthy subjects (452 (58) v 188 (69), p,0.005). Furthermore, double staining of DC stimulated with LPS, confirmed that 86% of the cells were fully matured.
Cytokine production by iDC and mDC from patients with RA and healthy controls We first investigated the production of proinflammatory (IL1, IL6, and TNFa), Th1 (IFNc, IL12), and Th2 (IL10) cytokines by iDC at day 6 and after full maturation with LPS (mDC, day 8) from 21 patients with RA and 18 healthy donors. Figures 2A and B show that iDC from patients with RA and from healthy subjects produced similar levels of proinflammatory, Th1 and Th2 cytokines. As expected, stimulation of iDC with LPS significantly increased the production of IL1, IL6, and TNFa in both groups. However, comparison of patients and controls showed clearly higher levels of IL1 (mean (SD); 341 (47) v 116 (7) pg/ml; p = 0.005), IL6 (6027 (1185) v 661 (220) pg/ml; p,0.005), and TNFa (3494 (762) v 587 (128); p,0.005) in RA. Fully matured DC produced higher levels of IL12 and similar levels of IFNc than iDC, and there were no differences between patients with RA and healthy controls ( fig 2B) . In contrast, the production of IL10 was significantly higher in mDC from patients with RA (225 (53) v 38 (15) pg/ml; p = 0.003) than in healthy subjects.
Triggering of FccR results in distinct cytokine
responses between patients with RA and healthy controls Because previous findings from our group suggested that DC from patients with RA have an increased expression of inhibitory FccRIIb, 15 we decided to test its repercussions on the production of cytokines. Therefore FccR were triggered with heat aggregated IgG immunoglobulins (HAGGS).
As expected, the addition of HAGGS to DC from healthy controls cocultured with LPS before maturation significantly increased production of TNFa (110%, p = 0.006) and IL6 (160%, p = 0.002) in comparison with DC cocultured with LPS alone (fig 3) . In contrast, additional FccR triggering of DC from patients with RA reduced the production of these cytokines with TNFa (238%, p = 0.03) and IL6 (240%, p = 0.03). After FccR stimulation, the production of IL1 decreased both in DC from patients with RA (263%, p = 0.008) and from healthy donors (238%, p,0.005 ). The secretion of IFNc (28% v 214%) and IL12 (267% v 265%) decreased equally in patients with RA and healthy donors, respectively, but was significant for only the latter.
The production of IL10 increased significantly upon FccR dependent stimulation by DC from patients with RA (57%, p = 0.01) and healthy controls (92%, p,0.01). Although the level of IL10 was already high in mDC of patients with RA ( fig 3) it further increased to 354 (44) pg/ml v 73 (16) pg/ml (p,0.005) in controls.
Because the expression of FccR changes during DC maturation we also investigated the effect of FccR engagement by IC on cytokine production by iDC. The production of IL1, IL6, TNFa, and IFNc by iDC was similar to that by mDC after triggering of FccR in both patients with RA and healthy controls, whereas opposite reactions were observed for IL12 and IL10 (table 1) .
Cytokine production by DC stimulated via FccR independent pathways (IFNc) Table 2 shows that the addition of IFNc to iDC dramatically increased production of IL6 (48-fold), TNFa (84-fold), and IL12 (82-fold) by DC from patients with RA and led to much higher levels of these cytokines in RA than in control DC. (40) 126 (25) 0.02 38 (15) 27 (12) 0.03
Results are shown as mean (SD).
During maturation with LPS, the addition of IFNc further increased the secretion of IL6, TNFa, and IL12 by DC both from patients with RA and controls.
Although the percentage increase of cytokine production by mDC was less than that of iDC, mDC from patients with RA secreted enormous amounts of these cytokines, which were significantly higher than the levels secreted by DC from controls.
In strong contrast, stimulation with IFNc of DC clearly decreased production of IL10 by iDC and mDC from both patients with RA and healthy controls.
DISCUSSION
We have previously observed an increased expression of FccRII, probably subtype IIb, on DC from patients with RA and suggested that this might function as a counter mechanism to suppress inflammation. 15 Therefore, we investigated whether this phenomenon has biological consequences. To this aim we studied the production of various proinflammatory, Th1, and Th2 cytokines by DC after triggering of FccR with IC and after FccR independent stimuli such as IFNc. Our results clearly show that fully matured DC from patients with RA produce significantly higher levels of proinflammatory (IL1, IL6, and TNFa) and Th2 (IL10) cytokines than those of healthy donors. These results are in line with previous reports, which suggest a balance towards proinflammatory cytokines and Th1 responses by inflammatory cells in RA. 6 8 40 Intriguingly, triggering of FccR, abundantly expressed on DC, resulted in clear differences in IL6 and TNFa production between DC from patients with RA and healthy controls. Whereas stimulation by IC in healthy subjects led to an increased production of IL6 and TNFa, the opposite effect was observed by DC from patients with RA. That FccR triggering leads to an increased production of TNFa by monocytes and macrophages from healthy donors has been previously reported. 41 42 However, we are the first to describe a reversed effect in RA and suggest a different balance of activation and inhibitory FccR on DC from patients with RA in comparison with controls. As only IL6 and TNFa and not IL1, IL10, IFNc, and IL12 are differentially influenced by the balance in FccR expression suggests that this is not a generalised phenomenon and might provide a new tool enabling the production of several cytokines to be tuned specifically. In agreement with recent observations, the balance of IL12 and IL10, two cytokines diametrically opposed in their function, altered dramatically upon FccR stimulation on DC. 29 30 Activation of FccR led to a skewed IL12/IL10 balance towards the latter in both groups but was more pronounced in RA.
The much higher production of cytokines after stimulation with LPS or IFNc by DC from patients with RA is intriguing and might suggest the presence of imprinting phenomena in DC. It is well known that DC development is influenced by a plethora of environmental factors which favour distinct DC phenotypes. DC obtained from patients with RA are probably primed by a variety of stimuli such as cytokines, chemokines which are abundantly present in the serum and joints of patients with RA. 4 5 8 Accumulating evidence suggests that the DC phenotype can be defined by its Th1/Th2 cytokine profile which, in turn, determines the polarisation of the T cell response. However, it remains a matter of debate how DC influence this decision and whether the ability to respond differently is acquired by environmental factors or is an intrinsic property. A large body of evidence points towards DC having a key role in the orchestration of the innate and adaptive immune responses. Furthermore, involvement of DC in the modulation and control of both central and peripheral tolerance is generally well established.
11 [43] [44] [45] DC perform these pivotal functions and the expression of both inhibitory and activation FccR is of paramount importance; this has been elegantly addressed by several studies. 29 46 47 Anderson et al showed that only macrophages stimulated with antigen directed to FccR result in the production of antigen-specific T cells, which preferentially produce Th2 cytokines. 29 Moreover, the development of immunity or tolerance against tumour antigens was largely dependent on the balance between activation or inhibitory FccR. 47 Additionally, the involvement of FccR in synovial inflammation was clearly demonstrated in several models of experimental arthritis and RA. 26-28 42 Our data might support the hypothesis that DC in RA represent a protective cell type but fail to orchestrate this protective effect to the full extent owing to an as yet unknown cause. This hypothesis is further underlined by preliminary data, which show that DC from patients with RA cannot increase the expression of FccRII to levels achieved by DC of healthy controls after certain stimuli (manuscript in preparation). Recently, genetic alterations in the regulatory regions in the FccRIIb gene were found. 48 49 However, both environmental and intrinsic factors may be implicated in determining the balance between inhibitory and activation FccR. Possibly, one or more of these potential factors is affected in RA. The profiles of cytokine production observed after FccR triggering and the differences between patients with RA and healthy controls strongly favour this hypothesis. However, an intrinsic defect cannot be excluded and is potentially reflected by the inability to fully employ their protective phenotype in vivo.
DC are preferentially located in the perivascular regions of the synovial tissue, where they fulfil an important role in the chemoattraction and instruction of other inflammatory cells. Therefore, from a therapeutic point of view, manipulation of cytokine profiles and behaviour of DC represents a very attractive strategy to orchestrate and control the autoimmunity seen in RA. The fact that our data show that triggering of FccR, at least partly, overrules cytokine production in response to activation of Toll-like receptors (LPS stimulation) is highly interesting. It was suggested recently that high levels of IL6 induced by activation of Toll-like receptors block the activity of regulatory T cells in vivo. This phenomenon might explain the beneficial effects of intravenous immunoglobulin seen in many diseases (reviewed by Mackay and Rosen 51 ). Strong evidence for a clinical effect in RA, however, is lacking and might be due to our suggested FccRIIb regulatory defect. 52 53 Further elucidation of the mechanisms involved in the regulation of FccRIIb might provide new clues for the modulation of DC function in autoimmune diseases such as RA.
In summary, the present study provides strong evidence that DC may play a part in the pathogenesis of RA owing to their high production of proinflammatory and Th1 cytokines, which is differentially regulated by FccR on DC from patients with RA and healthy controls. More insights into these mechanisms might provide new clues about the regulation of (auto)immunity and tolerance by DC in RA and might expand our therapeutic armamentarium to control this disease. 
